KR102160322B1 - 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도 - Google Patents

항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR102160322B1
KR102160322B1 KR1020157015490A KR20157015490A KR102160322B1 KR 102160322 B1 KR102160322 B1 KR 102160322B1 KR 1020157015490 A KR1020157015490 A KR 1020157015490A KR 20157015490 A KR20157015490 A KR 20157015490A KR 102160322 B1 KR102160322 B1 KR 102160322B1
Authority
KR
South Korea
Prior art keywords
ala
listeria
glu
lys
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157015490A
Other languages
English (en)
Korean (ko)
Other versions
KR20150099738A (ko
Inventor
피터 엠. 라우어
윌리엄 쥐. 한슨
저스틴 스코블
메레디스 라이 링 레옹
마르셀라 파쏘
더크 브록스테드
토마스 더블유. 주니어 두벤스키
Original Assignee
아두로 바이오테크, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아두로 바이오테크, 인코포레이티드 filed Critical 아두로 바이오테크, 인코포레이티드
Publication of KR20150099738A publication Critical patent/KR20150099738A/ko
Application granted granted Critical
Publication of KR102160322B1 publication Critical patent/KR102160322B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
KR1020157015490A 2012-12-27 2013-12-27 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도 Expired - Fee Related KR102160322B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US61/746,237 2012-12-27
US201361780744P 2013-03-13 2013-03-13
US61/780,744 2013-03-13
PCT/US2013/078119 WO2014106123A1 (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Publications (2)

Publication Number Publication Date
KR20150099738A KR20150099738A (ko) 2015-09-01
KR102160322B1 true KR102160322B1 (ko) 2020-09-25

Family

ID=51017446

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157015490A Expired - Fee Related KR102160322B1 (ko) 2012-12-27 2013-12-27 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도

Country Status (12)

Country Link
US (2) US9663557B2 (https=)
EP (1) EP2938627B1 (https=)
JP (2) JP2016503655A (https=)
KR (1) KR102160322B1 (https=)
CN (1) CN104955835B (https=)
AU (2) AU2013370210B2 (https=)
BR (1) BR112015015076A2 (https=)
CA (1) CA2888727A1 (https=)
EA (1) EA201590397A8 (https=)
MX (1) MX2015008329A (https=)
SG (2) SG10201700916SA (https=)
WO (1) WO2014106123A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CA2982543A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
AU2016262823A1 (en) 2015-05-18 2017-12-07 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
NZ752984A (en) 2016-11-22 2026-03-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
AU2019231783B2 (en) 2018-03-09 2023-11-16 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of Listeria strains
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
EP4168593A4 (en) 2020-06-23 2024-11-27 The Regents of the University of Colorado, a body corporate METHODS FOR DIAGNOSIS OF RESPIRATORY PATHOGENS AND PREDICTION OF EVOLUTIONS ASSOCIATED WITH COVID-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204516A1 (en) * 2000-03-29 2006-09-14 Yvonne Paterson Compositions and methods for enhancing the immunogenicity of antigens
WO2007103225A2 (en) * 2006-03-01 2007-09-13 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
CA2460014A1 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
EP2283112B1 (en) * 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
SMT201800444T1 (it) 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204516A1 (en) * 2000-03-29 2006-09-14 Yvonne Paterson Compositions and methods for enhancing the immunogenicity of antigens
WO2007103225A2 (en) * 2006-03-01 2007-09-13 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof

Also Published As

Publication number Publication date
US20140186387A1 (en) 2014-07-03
JP6671408B2 (ja) 2020-03-25
EP2938627A4 (en) 2016-12-14
WO2014106123A8 (en) 2016-06-16
MX2015008329A (es) 2016-03-01
US9663557B2 (en) 2017-05-30
AU2013370210A1 (en) 2015-06-18
WO2014106123A1 (en) 2014-07-03
AU2013370210A8 (en) 2016-06-23
KR20150099738A (ko) 2015-09-01
EP2938627B1 (en) 2019-03-20
JP2016503655A (ja) 2016-02-08
JP2018135355A (ja) 2018-08-30
EA201590397A8 (ru) 2016-08-31
SG11201502792TA (en) 2015-05-28
BR112015015076A2 (pt) 2018-10-30
EA201590397A1 (ru) 2016-02-29
CN104955835A (zh) 2015-09-30
SG10201700916SA (en) 2017-03-30
EP2938627A1 (en) 2015-11-04
US20170253637A1 (en) 2017-09-07
HK1215260A1 (zh) 2016-08-19
AU2018203555A1 (en) 2018-06-07
CA2888727A1 (en) 2014-07-03
CN104955835B (zh) 2020-04-17
AU2013370210B2 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
KR102160322B1 (ko) 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도
JP5998370B2 (ja) Ｅｇｆｒｖｉｉｉに対する免疫応答を誘発する方法および組成物
JP2011529077A (ja) Ｃ型肝炎の治療のための組成物および方法
JP2015534822A (ja) 条件的弱毒化細菌種ならびにその調製法および使用法
AU2013341242A1 (en) Facultatively attenuated bacterial species and methods of preparation and use thereof
TW201809274A (zh) 蛋白質表現強化子序列及其用途
HK1215260B (zh) 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
US20130323275A1 (en) Methods and compositions for inducing a t-cell response to plasmodium species
HK1190757B (en) Methods and compositions for inducing an immune response to egfrviii
HK40006687A (zh) 蛋白质表达增强子序列及其用途
HK1190757A (en) Methods and compositions for inducing an immune response to egfrviii

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230922

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230922